Literature DB >> 165243

Cellular events in zoster vesicles: relation to clinical course and immune parameters.

D A Stevens, R A Ferrington, G W Jordan, T C Merigan.   

Abstract

The cellular responses in zoster vesicles was studied chronologically in 30 patients, some of whom were compromised hosts with disseminated disease. Cell counts were low initially but rose abuptly later. Polymorphonuclear leukocytes predominated at all times in the vesicular fluid and in the cells adherent to the vesicle base. The abrupt rise in the number of cells generally coincided with an abrupt rise in the titer of vesicular interferon; both increases preceded resolution of local infection and cessation of cutaneous dissemination in disseminated disease, but the sequence of the increases was variable. The peak interferon titer correlated with cessation of dissemination better than did peak cell counts, and the timing of the local events contrasted with appearance of complement-fixing antibody, which commonly occurred after the resolution of disease. Possible interpretations are that a few sensitized lymphocytes may initiate the defensive response, produce interferon, and/or produce chemotactic factors that augment the polymorphonuclear response. The appearance of polymorphonuclear cells may be a nonspecific inflammatory response, or these cells or the deeper mononuclear infiltrate seen in biopsies may contribute to the rise in local interferon.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165243     DOI: 10.1093/infdis/131.5.509

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Tumour necrosis factor triggers granulocytes to internalize complement-coated virus particles.

Authors:  J A van Strijp; M E van der Tol; L A Miltenburg; K P van Kessel; J Verhoef
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion.

Authors:  J A Van Strijp; K P Van Kessel; M E van der Tol; J Verhoef
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Effect of respiratory syncytial virus and virus-antibody complexes on the oxidative metabolism of human neutrophils.

Authors:  T N Kaul; H Faden; P L Ogra
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

Review 4.  Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis.

Authors:  Maria A Nagel; Dallas Jones; Ann Wyborny
Journal:  J Neuroimmunol       Date:  2017-03-18       Impact factor: 3.478

5.  Direct inactivation of viruses by human granulocyte defensins.

Authors:  K A Daher; M E Selsted; R I Lehrer
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

6.  Varicella-zoster virus vasculopathy: immune characteristics of virus-infected arteries.

Authors:  Maria A Nagel; Igor Traktinskiy; Kurt R Stenmark; Maria G Frid; Alexander Choe; Don Gilden
Journal:  Neurology       Date:  2012-12-12       Impact factor: 9.910

7.  Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts.

Authors:  T Ihara; S E Starr; M Ito; S D Douglas; A M Arbeter
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Interaction of polymorphonuclear leukocytes and viruses in humans: adherence of polymorphonuclear leukocytes to respiratory syncytial virus-infected cells.

Authors:  H Faden; J J Hong; P L Ogra
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

9.  Virus-induced complement activation and neutrophil-mediated cytotoxicity against respiratory syncytial virus (RSV).

Authors:  T N Kaul; H Faden; R Baker; P L Ogra
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

10.  Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea.

Authors:  T M Tumpey; S H Chen; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.